Form 8-K - Current report:
SEC Accession No. 0001140361-23-009574
Filing Date
2023-03-02
Accepted
2023-03-02 07:55:18
Documents
13
Period of Report
2023-03-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10049140_8k.htm   iXBRL 8-K 28249
2 EXHIBIT 99.1 brhc10049140_ex99-1.htm EX-99.1 17151
  Complete submission text file 0001140361-23-009574.txt   189312

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20230302.xsd EX-101.SCH 3901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20230302_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20230302_pre.xml EX-101.PRE 16068
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10049140_8k_htm.xml XML 4244
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

IRS No.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 23696460
SIC: 2834 Pharmaceutical Preparations